86 related articles for article (PubMed ID: 20164040)
1. Expression of tissue inhibitors of metalloproteinase 1 (TIMP-1) in gastric cancer tissue.
Mroczko B; Lukaszewicz-Zajac M; Groblewska M; Czyzewska J; Gryko M; Guzińska-Ustymowicz K; Kemona A; Kedra B; Szmitkowski M
Folia Histochem Cytobiol; 2009 Jan; 47(3):511-6. PubMed ID: 20164040
[TBL] [Abstract][Full Text] [Related]
2. [Relationship of expression unbalance of matrix metalloproteinase and tissue inhibitor of metalloproteinase to invasiveness and metastasis in gastric carcinomas].
Li L; Zhang S; Lin H; Lin JY
Ai Zheng; 2002 Mar; 21(3):305-10. PubMed ID: 12452001
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological significance of MMP-2 and its specific inhibitor TIMP-2 in gastric cancer.
Alakus H; Grass G; Hennecken JK; Bollschweiler E; Schulte C; Drebber U; Baldus SE; Metzger R; Hölscher AH; Mönig SP
Histol Histopathol; 2008 Aug; 23(8):917-23. PubMed ID: 18498066
[TBL] [Abstract][Full Text] [Related]
4. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
5. Coexpression of Matrix Metalloproteinase-7 and Tissue Inhibitor of Metalloproteinase-1 as a Prognostic Biomarker in Gastric Cancer.
Zhang Y; Qin L; Ma X; Wang Y; Wu Y; Jiang J
Dis Markers; 2020; 2020():8831466. PubMed ID: 33005257
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase 2 (MMP-2) and their tissue inhibitor 2 (TIMP-2) in gastric cancer patients.
Łukaszewicz-Zając M; Mroczko B; Guzińska-Ustymowicz K; Pryczynicz A; Gryko M; Kemona A; Kędra B; Szmitkowski M
Adv Med Sci; 2013; 58(2):235-43. PubMed ID: 24384769
[TBL] [Abstract][Full Text] [Related]
7. Expression of metalloproteinase-2, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in transitional cell carcinoma of upper urinary tract: correlation with tumor stage and survival.
Miyata Y; Kanda S; Nomata K; Hayashida Y; Kanetake H
Urology; 2004 Mar; 63(3):602-8. PubMed ID: 15028476
[TBL] [Abstract][Full Text] [Related]
8. Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples.
Pesta M; Holubec L; Topolcan O; Cerna M; Rupert K; Holubec LS; Treska V; Kormunda S; Elgrova L; Finek J; Cerny R
Anticancer Res; 2005; 25(5):3387-91. PubMed ID: 16101153
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.
Wu ZS; Wu Q; Yang JH; Wang HQ; Ding XD; Yang F; Xu XC
Int J Cancer; 2008 May; 122(9):2050-6. PubMed ID: 18172859
[TBL] [Abstract][Full Text] [Related]
10. Pre-treatment serum and plasma levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) in gastric cancer patients.
Mroczko B; Groblewska M; Łukaszewicz-Zajac M; Bandurski R; Kedra B; Szmitkowski M
Clin Chem Lab Med; 2009; 47(9):1133-9. PubMed ID: 19728856
[TBL] [Abstract][Full Text] [Related]
11. Expression of tissue inhibitors of metalloproteinases (TIMPs) in gastric cancer.
Joo YE; Seo KS; Kim HS; Rew JS; Park CS; Kim SJ
Dig Dis Sci; 2000 Jan; 45(1):114-21. PubMed ID: 10695623
[TBL] [Abstract][Full Text] [Related]
12. Expression of Vav3 protein and its prognostic value in patients with gastric cancer.
Tan B; Li Y; Shi X; Fan L; Zhao Q; Liu Y; Tan M; Liu Q; Jia N
Pathol Res Pract; 2017 May; 213(5):435-440. PubMed ID: 28285969
[TBL] [Abstract][Full Text] [Related]
13. The absence of immunoreactivity for tissue inhibitor of metalloproteinase-1 (TIMP-1), but not for TIMP-2, protein is associated with a favorable prognosis in aggressive breast carcinoma.
Kuvaja P; Talvensaari-Mattila A; Pääkkö P; Turpeenniemi-Hujanen T
Oncology; 2005; 68(2-3):196-203. PubMed ID: 16006757
[TBL] [Abstract][Full Text] [Related]
14. Expression of matrix metalloproteinase-9 in the neoplastic and interstitial inflammatory infiltrate cells in gastric cancer.
Mroczko B; Łukaszewicz-Zajac M; Guzińska-Ustymowicz K; Gryko M; Czyzewska J; Kemona A; Kedra B; Szmitkowski M
Folia Histochem Cytobiol; 2009 Jan; 47(3):491-6. PubMed ID: 20164037
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer.
Hilska M; Roberts PJ; Collan YU; Laine VJ; Kössi J; Hirsimäki P; Rahkonen O; Laato M
Int J Cancer; 2007 Aug; 121(4):714-23. PubMed ID: 17455256
[TBL] [Abstract][Full Text] [Related]
16. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
17. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
[TBL] [Abstract][Full Text] [Related]
18. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker.
Wang CS; Wu TL; Tsao KC; Sun CF
Ann Clin Lab Sci; 2006; 36(1):23-30. PubMed ID: 16501233
[TBL] [Abstract][Full Text] [Related]
19. Tissue inhibitor of metalloproteinase 1 (TIMP-1) as a biomarker in gastric cancer: a review.
Grunnet M; Mau-Sørensen M; Brünner N
Scand J Gastroenterol; 2013 Aug; 48(8):899-905. PubMed ID: 23834019
[TBL] [Abstract][Full Text] [Related]
20. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
Wei QY; Wu YQ; Fan SQ
Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
